BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 32360477)

  • 1. Tau immunotherapies: Lessons learned, current status and future considerations.
    Sandusky-Beltran LA; Sigurdsson EM
    Neuropharmacology; 2020 Sep; 175():108104. PubMed ID: 32360477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tau immunotherapy for Alzheimer's disease.
    Pedersen JT; Sigurdsson EM
    Trends Mol Med; 2015 Jun; 21(6):394-402. PubMed ID: 25846560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tau Immunotherapy.
    Sigurdsson EM
    Neurodegener Dis; 2016; 16(1-2):34-8. PubMed ID: 26551002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tau Immunotherapies for Alzheimer's Disease and Related Tauopathies: Progress and Potential Pitfalls.
    Sigurdsson EM
    J Alzheimers Dis; 2018; 64(s1):S555-S565. PubMed ID: 29865056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A walk through tau therapeutic strategies.
    Jadhav S; Avila J; Schöll M; Kovacs GG; Kövari E; Skrabana R; Evans LD; Kontsekova E; Malawska B; de Silva R; Buee L; Zilka N
    Acta Neuropathol Commun; 2019 Feb; 7(1):22. PubMed ID: 30767766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Overview on the Clinical Development of Tau-Based Therapeutics.
    Medina M
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29641484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies.
    Schroeder SK; Joly-Amado A; Gordon MN; Morgan D
    J Neuroimmune Pharmacol; 2016 Mar; 11(1):9-25. PubMed ID: 26538351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau Immunotherapies for Alzheimer's Disease and Related Tauopathies: Status of Trials and Insights from Preclinical Studies.
    Sigurdsson EM
    J Alzheimers Dis; 2024 Feb; ():. PubMed ID: 38427486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tau Proteins and Tauopathies in Alzheimer's Disease.
    Chong FP; Ng KY; Koh RY; Chye SM
    Cell Mol Neurobiol; 2018 Jul; 38(5):965-980. PubMed ID: 29299792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.
    Sigurdsson EM
    J Alzheimers Dis; 2008 Oct; 15(2):157-68. PubMed ID: 18953105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tau immunotherapy and imaging.
    Sigurdsson EM
    Neurodegener Dis; 2014; 13(2-3):103-6. PubMed ID: 24029727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Status of Clinical Trials on Tau Immunotherapies.
    Ji C; Sigurdsson EM
    Drugs; 2021 Jul; 81(10):1135-1152. PubMed ID: 34101156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for Alzheimer's disease.
    Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer's Disease.
    Vander Zanden CM; Chi EY
    J Pharm Sci; 2020 Jan; 109(1):68-73. PubMed ID: 31647950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent therapeutic strategies targeting beta amyloid and tauopathies in Alzheimer's disease.
    Madav Y; Wairkar S; Prabhakar B
    Brain Res Bull; 2019 Mar; 146():171-184. PubMed ID: 30634016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapeutic approaches for Alzheimer's disease.
    Wisniewski T; Goñi F
    Neuron; 2015 Mar; 85(6):1162-76. PubMed ID: 25789753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for targeting tau pathology in Alzheimer's disease and tauopathies.
    Rosenmann H
    Curr Alzheimer Res; 2013 Mar; 10(3):217-28. PubMed ID: 23534533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances and considerations in AD tau-targeted immunotherapy.
    Bittar A; Bhatt N; Kayed R
    Neurobiol Dis; 2020 Feb; 134():104707. PubMed ID: 31841678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting tau only extracellularly is likely to be less efficacious than targeting it both intra- and extracellularly.
    Congdon EE; Jiang Y; Sigurdsson EM
    Semin Cell Dev Biol; 2022 Jun; 126():125-137. PubMed ID: 34896021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for tauopathies.
    Gu J; Sigurdsson EM
    J Mol Neurosci; 2011 Nov; 45(3):690-5. PubMed ID: 21739165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.